biological therapies such as anti tumor necrosis factor α (TNFα) drug infliximab (IFX), have led to substantial improvements in the treatment of Crohn’s disease (CD) patients. However, approximately a third of them do not have a response during induction period (primary non-response). This fact highlights the clinical need to identify biomarkers that predict response, providing the bases for personalized medicine.